In a groundbreaking announcement, Candel Therapeutics, Inc. a leading clinical-stage biopharmaceutical company dedicated to advancing multimodal biological immunotherapies to combat cancer, specified two significant abstracts had been accepted for presentation at the imminent 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. The esteemed event will take place from May 31 to June 4, 2024, in Chicago, IL. These showcases will reveal pivotal early-stage data related to two proprietary investigational therapies specifically designed for patients with recurrent high-grade glioma and advanced non-small cell lung cancer (NSCLC).
The first presentation will unfold insights regarding an ongoing phase 1 clinical trial investigating the potential of CAN-3110 in patients diagnosed with recurrent high-grade glioma, a notoriously difficult cancer to treat. Particularly notable here is the focus on patients within cohort C who underwent multiple doses of CAN-3110, receiving up to six injections. The data will spotlight the viability and tolerability of this therapeutic approach, which could represent a promising avenue for more effective glioma treatment.
Moving into advanced lung cancer, the second presentation takes a different tack by concentrating on overall survival data from a phase 2 trial employing a mutable therapeutic approach. Specifically, this regime involved the combination of CAN-2409 alongside valacyclovir, working in unison with continued immune checkpoint inhibitor (ICI) treatment. These results target patients with non-resectable, stage III/IV NSCLC demonstrating poor responses to first-line anti-PD(L)1 therapy.
The presentation promises to provide invaluable information about the effectiveness of continued ICI treatment alongside Candel’s CAN-2409 and valacyclovir combination. Given the high prevalence and deadly nature of NSCLC and the often inadequate responses to anti-PD(L)1 therapy in late-stage patients, these findings could hold significant implications for improving outcomes in this patient population.
In conclusion, the presentations from Candel Therapeutics at the 2024 ASCO Annual Meeting are set to offer fresh perspectives on the management of recurrent high-grade glioma and non-responsive late-stage NSCLC. Spotlighting the inventiveness and focused dedication of Candel Therapeutics in revolutionizing cancer treatment, these presentations will undoubtedly garner attention from the oncology community and beyond. By advancing our understanding of how cancer can be combated, these studies provide hope for better outcomes in two particularly challenging types of malignancy.
Comments